In defense of the somatic mutation theory of cancer

BioEssays

Volumn 33, Issue 5, 2011, Pages 341-343

  Vaux, David L ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

Cancer; Carcinogenesis; Clone; Mutation; Oncogene

Indexed keywords

BCR ABL PROTEIN; IMATINIB; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CELL DIVISION; CELL PROLIFERATION; CHROMOSOME 14; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DNA REPAIR; DNA SEQUENCE; FOLLICULAR LYMPHOMA; GENE LOCUS; HUMAN; ONCOGENE C MYC; PLASMACYTOMA; SOMATIC CELL; SOMATIC MUTATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; HUMANS; LEUKEMIA, MYELOID; MUTATION; NEOPLASMS;

EID: 79954575999     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201100022     Document Type: Article

References (25)

1. Boveri T. 1914. Zur Frage der Entstehung maligner Tumoren, Vol. 4. Jena, Germany: Gustav Fischer; p. 64.
2. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
3. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. 1999. Genetic instability and Darwinian selection in tumours. Trends Cell Biol 9: M57-60.
4. Lane DP. 1992. Cancer. p53, guardian of the genome. Nature 358: 15-6.
5. Knudson AG. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157-62.
6. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128: 683-92.
7. Bernard O, Cory S, Gerondakis S, Webb E, et al. 1983. Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours. EMBO J. 12: 2375-83.
8. Adams JM, Harris AW, Pinkert CA, Corcoran LM, et al. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-8.
9. Barrett JC. 1993. Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect 100: 9-20.
10. Denissenko MF, Pao A, Tang M, Pfeifer GP. 1996. Preferential formation of benzo. Science 274: 430-2.
11. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, et al. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-36.
12. Henderson S, Huen D, Rowe M, Dawson C, et al. 1993. Epstein-Barr virus coded bhrf1 protein, a viral homolog of bcl 2, protects human b cells from programmed cell death. Proc Natl Acad Sci USA 90: 8479-83.
13. Varmus HE. 1983. Using retroviruses as insertional mutagens to identify cellular oncogenes. Prog Clin Biol Res 119: 23-35.
14. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-76.
15. Mintz B, Illmensee K. 1975. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA 72: 3585-9.
16. Illmensee K, Mintz B. 1976. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc Natl Acad Sci USA 73: 549-53.
17. Hochedlinger K, Blelloch R, Brennan C, Yamada Y, et al. 2004. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 18: 1875-85.
18. Vaux DL, Cory S, Adams JM. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-2.
19. Gauwerky CE, Haluska FG, Tsujimoto Y, Nowell PC, et al. 1988. Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene. Proc Natl Acad Sci USA 85: 8548-52.
20. Strasser A, Harris AW, Bath ML, Cory S. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348: 331-3.
21. Dong J, Phelps RG, Qiao R, Yao S, et al. 2003. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63: 3883-5.
22. Podsypanina K, Politi K, Beverly LJ, Varmus HE. 2008. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci USA 105: 5242-7.
23. Martins CP, Brown-Swigart L, Evan GI. 2006. Modelling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323-34.
24. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, et al. 2002. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645-52.
25. Shah NP, Tran C, Lee FY, Chen P, et al. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.